STUDY GOALS AND OBJECTIVES
The objectives of the study are to present a comprehensive look at disorders that have a female incidence rate of over 70%. Markets are divided according to disorders or diseases. Many of the products are used in multiple markets. The report is directed to decision-makers in the various women's disorder and disease markets to present insight into those arenas for current and future development.
REASONS FOR STUDY
This BCC study is presented to heighten the awareness of women's disorders and identify pharmaceutical preparations, devices and important advancements in the women's disorders markets. The study analyzes the new therapeutics and diagnostics for women's disorders from a current standpoint as well as a potential standpoint. It also addresses issues and trends affecting the market. Manufacturers of pharmaceutical products, devices and test kits for women's disorders have stepped up the pace of research and development as the engine driving growth in all markets is research and development. Because of the evolving nature of the many areas of women's disorders executives involved in specific women's disorders markets must remain ever vigilant of the changing environment and strive to keep abreast of current and potential opportunities.
SCOPE OF STUDY
The report is designed to be a comprehensive tool to provide an in-depth look at women's disorders. The geographic scope of the report is the United States. The report identifies the different areas of women's disorders; gives a brief explanation of the disorder; cites risk factors, incidence and mortality; presents current treatments, market size and market participants; and presents potential treatments in research and development, potential market size and market participants. The report describes the industry in detail, its relationship to the healthcare industry, its participants, and its trends for the future.
Within the New Therapeutics and Diagnostics for Women's Disorders, categories with over 70% female incidence are addressed including:
- Autoimmune Diseases
- Cancer
- Gynecological Diseases and Infections
- Kidney and Urologic Diseases and Conditions
- Reproductive-Related Therapeutics and Diagnostics
- Rheumatoid Arthritis and Osteoporosis
- Sexual Dysfunction
All categories are further broken down into specific disorders and diseases. Each subsegment is discussed in detail, describing disorders and diseases, identifying current and potential products on the market, measuring current and potential market size, identifying current and potential market drivers, forecasting for 2000 and 2005, assessing current and potential competitors, and identifying current competitor market shares.
METHODOLOGY AND INFORMATION SOURCES
The information and analysis presented in this BCC report are based on an extensive first hand interviews with primary executives, product managers, and clinical specialists in the areas of women's disorders. Background information was obtained from various government, , medical journal and trade magazines and interviews with doctors and nurses. Key information from published literature was used to conduct interviews with over 125 industry participants to validate and obtain expert opinions on current and future trends in women's disorders. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as formulating market projections.
All market data pertain to the U.S. market at the manufacturer's level. Data are expressed in current U.S. dollars. The base year was 1999. Historical data are provided for 1998 and forecast data are provided for 2000 and 2005. Historical, base year and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 1999 base year. All markets represent revenues derived from women only with an incidence rate of 70% or higher.
ANALYST CREDENTIALS
Mary Anne Crandall is a RN/Instructor/Medical Analyst specializing in the pharmaceuticals industry.
Report Code: BIO043B, Published: January 2001, Analyst: Mary Anne Crandall
